WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555484

CAS#: 2244904-70-7

Description: BAY-293 is a potent SOS1 inhibitor that blocks RAS activation via disruption of the RAS-SOS1 interaction. BAY-293) selectively inhibits the KRAS-SOS1 interaction with an IC50 of 21 nM and is a valuable chemical probe for future investigations.

Price and Availability

Size Price Shipping out time Quantity
5mg USD 415 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-25. Prices are subject to change without notice.

BAY-293, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 555484
Name: BAY-293
CAS#: 2244904-70-7
Chemical Formula: C25H28N4O2S
Exact Mass: 448.1933
Molecular Weight: 448.585
Elemental Analysis: C, 66.94; H, 6.29; N, 12.49; O, 7.13; S, 7.15

Related CAS #: 2244904-70-7   2244904-69-4 (S-isomer)   2244904-14 (racemic)    

Synonym: BAY-293; BAY 293; BAY293;

IUPAC/Chemical Name: (R)-6,7-dimethoxy-2-methyl-N-(1-(4-(2-((methylamino)methyl)phenyl)thiophen-2-yl)ethyl)quinazolin-4-amine


InChi Code: InChI=1S/C25H28N4O2S/c1-15(24-10-18(14-32-24)19-9-7-6-8-17(19)13-26-3)27-25-20-11-22(30-4)23(31-5)12-21(20)28-16(2)29-25/h6-12,14-15,26H,13H2,1-5H3,(H,27,28,29)/t15-/m1/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Hillig RC, Sautier B, Schroeder J, Moosmayer D, Hilpmann A, Stegmann CM,
Werbeck ND, Briem H, Boemer U, Weiske J, Badock V, Mastouri J, Petersen K,
Siemeister G, Kahmann JD, Wegener D, Böhnke N, Eis K, Graham K, Wortmann L, von
Nussbaum F, Bader B. Discovery of potent SOS1 inhibitors that block RAS
activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci U S A.
2019 Feb 12;116(7):2551-2560. doi: 10.1073/pnas.1812963116. Epub 2019 Jan 25.
PubMed PMID: 30683722; PubMed Central PMCID: PMC6377443.